QUICKVUE RSV 10 by QUIDEL CORP. | FDA 510(k) Summary

The QuickVue RSV 10 test is an immunoassay that allows for the rapid, qualitative detection of respiratory syncytial virus (RSV) antigen directly from nasopharyngeal swab and nasopharyngeal aspirate/wash specimens for symptomatic pediatric patients (less than six years old). The test is intended for use as an aid in the rapid diagnosis of acute RSV infection. Negative results do not preclude RSV infection and should not be used as the sole basis for treatment or for other management decisions. A negative test is presumptive. It is recommended that negative test results be confirmed by cell culture. The test is intended for professional and laboratory use.

Device Description

The QuickVue RSV 10 test is a lateral-flow immunoassay that uses monoclonal antibodies that are specific for RSV antigens. The test is specific to RSV antigen with no known cross-reactivity to normal flora or other known respiratory pathogens. Nasopharyngeal swabs and nasopharyngeal aspirate/wash serve as specimens for this test. For a liquid specimen such as a nasopharyngeal aspirate/wash, the specimen is added directly to the reagent tube and rehydrates the reagent. When a nasopharyngeal swab is used, the reagent is first rehydrated with the provided reagent solution and the swab specimen is then inserted into the reagent tube. The reagent interacts with the specimen and facilitates exposure of the appropriate viral antigens to the antibodies used in the test. The test strip is placed in the reagent tube for 10 minutes. During this time, the specimen will react with the reagents in the test strip. If the specimen contains RSV antigens, a pink-to-red Test Line, along with a blue procedural Control Line will appear on the Test Strip indicating a positive result. If RSV antigen is not present, or is present at very low levels, only a blue procedural Control Line will appear.

AI/ML Overview

The QuickVue® RSV 10 is an immunoassay for rapid, qualitative detection of respiratory syncytial virus (RSV) antigen in nasopharyngeal specimens from symptomatic pediatric patients (less than six years old).

Here's an analysis of its acceptance criteria and supporting study information:

1. Acceptance Criteria and Reported Device Performance

The document does not explicitly state pre-defined acceptance criteria (e.g., minimum sensitivity/specificity thresholds). Instead, it presents the performance data against a predicate device and states that "These studies demonstrated the substantial equivalence of the QuickVue RSV 10 test to existing products already marketed." Substantial equivalence is the primary regulatory standard for 510(k) devices.

To infer the performance that was found acceptable, we look at the provided comparator data. The "Summary of Performance Data" indicates that sensitivity and specificity were calculated against viral culture, which is generally considered the gold standard for RSV detection at the time of this submission. While the exact numerical performance metrics (sensitivity, specificity) are not provided in the snippet, their calculation against viral culture is highlighted as a key study.

Table of Performance (Based on information provided, specific values are not available in the extract):

Metric	Acceptance Criteria (Implied)	Reported Device Performance (Specific values not in extract)
Sensitivity (vs. culture)	Performance comparable to the predicate device (QuickVue RSV test) and demonstrating substantial equivalence.	Calculated (specific values not provided)
Specificity (vs. culture)	Performance comparable to the predicate device and demonstrating substantial equivalence.	Calculated (specific values not provided)
Reproducibility	Demonstrates intra- and inter-operator and laboratory consistency.	Demonstrated
Analytical Performance	Meets established specifications for stability, LOD, cross-reactivity, etc.	Demonstrated

2. Sample Size and Data Provenance

Sample Size for Test Set: Not explicitly stated in the provided text for the multi-center field clinical study.
Data Provenance: The multi-center field clinical study implies data was collected from multiple clinical sites. The country of origin is not specified but given the submitter (Quidel Corporation, San Diego, CA) and the FDA filing, it is likely the U.S. The study was a prospective multi-center field clinical study.

3. Number of Experts and Qualifications for Ground Truth

The document does not specify the number of experts or their qualifications for establishing the ground truth for the test set.

4. Adjudication Method for the Test Set

The document does not specify an adjudication method.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

No Multi-Reader Multi-Case (MRMC) comparative effectiveness study is mentioned. The study focuses on the device's performance against a gold standard (viral culture) and its equivalence to a predicate device, not on how human readers improve with AI assistance (as this is not an AI device).

6. Standalone Performance

Yes, a standalone performance study was done. The "multi-center field clinical study" aimed to "document the performance characteristics of the test," including sensitivity and specificity, by comparing the device's results directly to viral culture. This is a standalone assessment of the algorithm's (or, in this case, the test's) ability to detect RSV.

7. Type of Ground Truth Used

The primary ground truth used for the clinical study was viral culture.

8. Sample Size for the Training Set

The document does not mention a "training set" in the context of machine learning, as this is not an AI/ML device. It's a serological immunoassay. Therefore, there's no training set in that sense. The analytical studies involved panels of test samples at various RSV concentrations for reproducibility and analytical performance, but these are not a "training set."

9. How the Ground Truth for the Training Set Was Established

As noted above, there is no "training set" in the AI/ML context for this device. For the analytical studies, the ground truth was established by preparing test samples with known RSV concentrations.

Summary

{0}------------------------------------------------

Jennifer Hankard

QuickVue® RSV 10

serological reagents

July 8, 2010

K101918

Submitted By:

Quidel Corporation 10165 McKellar Court San Diego, California 92121 Telephone: 858-552-7910 858-646-8045 Fax:

Respiratory Syncytial Virus (RSV) Test

QuickVue RSV test (K061008 and K070747)

21 CFR 866.3480 / Respiratory syncytial virus

SEP 2 4 2010

Submission Contact:

Date Prepared:

Device Trade Name:

Common Name:

Predicate Device:

Device Classification/Name:

Intended Use:

These tests are used to aid in the diagnosis of disease caused by respiratory syncytial viruses and provides epidemiological information on these diseases (21 CFR 866.3480). The Food and Drug Administration has classified serological test systems for the detection of respiratory syncytial virus as Class l.

{1}------------------------------------------------

Physiologic Basis of the Test:

Respiratory syncytial virus (RSV) is a single stranded (negative strand) RNA virus of the Paramyxoviridae family. It is the causative agent of a highly contagious, acute, viral infection of the respiratory tract in pediatric populations. Nearly half of all children become infected by their first year of life. It is also the maior viral cause of nosocomial illness in children already hospitalized for other reasons. In the United States. RSV is estimated to be responsible for 73,400 to 126,300 hospitalizations annually for bronchiolitis and pneumonia alone among children younger than 1 year. In children hospitalized with RSV infection, it is believed to be the most common viral cause of death in children younger than 5 years, particularly in children younger than one year. Among children hospitalized with RSV infection, the mortality rate is estimated to be as low as 0.3% to 1.0% of hospitalized children and in the range of 2.5% to 4.0% for hospitalized children with underlying cardiac or pulmonary disease.

Nasopharvngeal swabs and nasopharyngeal aspirate/wash serve as specimens for this test. For a liquid specimen such as a nasopharyngeal aspirate/wash, the specimen is added directly to the reagent tube and rehydrates the reagent. When a nasopharyngeal swab is used, the reagent is first rehydrated with the provided reagent solution and the swab specimen is then inserted into the reagent tube.

The reagent interacts with the specimen and facilitates exposure of the appropriate viral antigens to the antibodies used in the test. The test strip is placed in the reagent tube for 10 minutes. During this time, the specimen will react with the reagents in the test strip.

If the specimen contains RSV antigens, a pink-to-red Test Line, along with a blue procedural Control Line will appear on the Test Strip indicating a positive result. If RSV antigen is not present, or is present at very low levels, only a blue procedural Control Line will appear.

Device Description:

Device Comparison:

{2}------------------------------------------------

Features	QuickVue RSV 10 test(Proposed)	QuickVue RSV test(K061008 and K070747)
Intended Use	The QuickVue RSV 10 test is animmunoassay that allows for therapid, qualitative detection ofrespiratory syncytial virus (RSV)antigen directly from nasopharyngealswab and nasopharyngealaspirate/wash specimens forsymptomatic pediatric patients (lessthan six years old). The test isintended for use as an aid in therapid diagnosis of acute RSVinfection. Negative results do notpreclude RSV infection and shouldnot be used as the sole basis fortreatment or for other managementdecisions. A negative test ispresumptive. It is recommended thatnegative test results be confirmed bycell culture. The test is intended forprofessional and laboratory use.	The QuickVue RSV test is a dipstickimmunoassay, which allows for therapid, qualitative detection ofrespiratory syncytial virus (RSV)antigen (viral fusion protein) directlyfrom nasopharyngeal swab,nasopharyngeal aspirate,nasal/nasopharyngeal washspecimens for symptomatic pediatricpatients (eighteen years of age andyounger). The test is intended foruse as an aid in the diagnosis ofacute respiratory syncytial viralinfections. It is recommended thatnegative test results be confirmed bycell culture. Negative results do notpreclude RSV infection and it isrecommended that they not be usedas the sole basis for treatment orother management decisions. Thetest is intended for professional andlaboratory use.
Specimen Types	Nasopharyngeal swab,Nasopharyngeal aspirate/wash	Nasopharyngeal swab,Nasopharyngeal aspirate/washNasal wash
Reagent	Lyophilized buffer containingdetergents	Liquid buffer solution containingdetergents
Read Result Time	10 Minutes	15 Minutes
Format	Lateral-flow immunoassay dipstick	Lateral-flow immunoassay dipstick
Control Features	Procedural Control LineClearing of background	Procedural Control LineClearing of background
External Controls	Positive RSV swabRSV negative swab coated withStreptococcus C antigen	Positive RSV swabRSV negative swab coated withStreptococcus C antigen

・

! ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------

{3}------------------------------------------------

Summary of Performance Data:

Numerous studies were undertaken to document the performance characteristics and the substantial equivalence of the test to the predicate device. These studies included the followina:

1. A multi-center field clinical study was undertaken to document the performance characteristics of the test. Sensitivity and specificity were calculated using nasopharyngeal swabs and nasopharyngeal aspirate/wash specimens compared to viral culture.
1. A reproducibility study was performed to demonstrate intra- and inter-operator reproducibility and intra- and inter-laboratory reproducibility with a panel of test samples at various RSV concentrations.
1. Analytical studies demonstrated specimen transport and stability, intra- and inter-lot consistency, analytical sensitivity, limit of detection, kit stability, cross reactivity, analytical specificity, lack of interference with various substances, and test robustness with variations in the test method.

Conclusion:

These studies demonstrated the substantial equivalence of the QuickVue RSV 10 test to existing products already marketed.

{4}------------------------------------------------

Image /page/4/Picture/0 description: The image shows the logo for the Department of Health & Human Services USA. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" around the perimeter. Inside the circle is a stylized symbol that resembles an abstract caduceus or a series of flowing lines, possibly representing health and human services.

Food and Drug Administration 10903 New Hampshire Avenue Document Mail Center - WO66-0609 Silver Spring, MD 20993-0002

Quidel Corporation c/o Jennifer S. Hankard Director, Regulatory Affairs and Quality Assurance 10165 McKellar Court San Diego, CA 92121

SEP 2 4 2010

Re: K101918

Trade/Device Name: QuickVue®RSV 10 Regulation Number: 21 CFR §866.3480 Respiratory syncytial virus serological reagents Regulation Name: Class I Regulatory Class: Product Code: GQG July 8, 2010 Dated: July 9, 2010 Received:

Dear Ms. Hankard,

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

{5}------------------------------------------------

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.

Sincerely yours.

Uve Sciref for

Sally A. Hojvat, M.Sc., Ph.D. Director Division of Microbiology Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health

Enclosure

{6}------------------------------------------------

Indications for Use

SEP 2 4 2010

12101918 510{k) Number (if known):

Device Name: QuickVue RSV 10

Indications For Use:

Prescription Use × (Part 21 CFR 801 Subpart D) AND/OR

Over-The-Counter Use (21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

Ihe Self
Division Sign-Off

Office of In Vitro Diagnostic Device Evaluation and Safety

Page 1 of

510(k) io 1718

Regulation Number and Section

§ 866.3480 Respiratory syncytial virus serological reagents.

(a)
Identification. Respiratory syncytial virus serological reagents are devices that consist of antigens and antisera used in serological tests to identify antibodies to respiratory syncytial virus in serum. Additionally, some of these reagents consist of respiratory syncytial virus antisera conjugated with a fluorescent dye (immunofluorescent reagents) and used to identify respiratory syncytial viruses from clinical specimens or from tissue culture isolates derived from clinical specimens. The identification aids in the diagnosis of respiratory syncytial virus infections and provides epidemiological information on diseases caused by these viruses. Respiratory syncytial viruses cause a number of respiratory tract infections, including the common cold, pharyngitis, and infantile bronchopneumonia.(b)
Classification. Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 866.9.